Pesquisar
Cyclerion Therapeutics Inc
CYCNAdicionar à lista de desejos
3.370USD
-0.020-0.59%
Horário de mercado （ET）Cotações atrasadas em 15 min
12.88MValor de mercado
PerdaP/L TTM
Mais detalhes de Cyclerion Therapeutics Inc Empresa
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Informações de Cyclerion Therapeutics Inc
Código da empresaCYCN
Nome da EmpresaCyclerion Therapeutics Inc
Data de listagemMar 18, 2019
CEOGraul (Regina M)
Número de funcionários1
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 18
Endereço301 Binney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone16176217722
Sitehttps://www.cyclerion.com/
Código da empresaCYCN
Data de listagemMar 18, 2019
CEOGraul (Regina M)
Executivos da empresa Cyclerion Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
--
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
--
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Cyclerion Therapeutics Inc?
Os cinco principais acionistas de Cyclerion Therapeutics Inc são: Dr. Peter M. Hecht, Ph.D.
Quantas instituições possuem ações da Cyclerion Therapeutics Inc (CYCN)?
Em 2026Q1, 37 instituições possuíam ações da Cyclerion Therapeutics Inc, com valor de mercado aproximado de 318.08K, representando 7.35% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -667233.00.